

KASTEN BERNARD L  
Form 4/A  
August 15, 2011

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
KASTEN BERNARD L

2. Issuer Name and Ticker or Trading Symbol  
CLEVELAND BIOLABS INC [CBLI]

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)

(Last) (First) (Middle)  
C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET  
  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
08/15/2011

Director  10% Owner  
 Officer (give title below)  Other (specify below)

BUFFALO,, NY 14203

4. If Amendment, Date Original Filed(Month/Day/Year)  
08/15/2011

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3)           | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |   |                             |
|---|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|---|-----------------------------|
|   |                                      |  |                                | (A) or (D)  | Price   |  |                                   |   |                             |
|   |                                      |  |                                | Code  | V   | Amount   |                                   |   |                             |
| Common Stock, par value \$0.005 per share | 08/15/2011                           |  | P                              | 5,000   | A   | \$ 2.58  | 32,656                            | I | See footnote <sup>(1)</sup> |
| Common Stock, par value \$0.005 per share | 08/15/2011                           |  | P                              | 5,000   | A   | \$ 2.6   | 37,656                            | D |                             |

Edgar Filing: KASTEN BERNARD L - Form 4/A

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|--|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title                                      | Amount or Number of Shares   |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| KASTEN BERNARD L<br>C/O CLEVELAND BIOLABS, INC.<br>73 HIGH STREET<br>BUFFALO, NY 14203 |               | X         |         |       |

## Signatures

/s/ Leah Brownlee Attorney-in-fact for Bernard L. Kasten

08/15/2011

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares were acquired through a brokerage account in the name of Mr. Kasten's daughter. Mr. Kasten has voting and investment power over the shares of common stock held in this brokerage account. As such, Mr. Kasten is deemed to have beneficial ownership of the shares of common stock held through this brokerage account.

### Remarks:

This Amendment corrects an error in column 5 of Table I, which previously included derivative securities beneficially owned

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

## Edgar Filing: KASTEN BERNARD L - Form 4/A

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.